# BioNTech Autogene Cevumeran mRNA Vaccine Keeps 87.5% of Pancreatic Cancer Responders Alive at Six Years, Versus 13% Standard Survival in MSK Phase 1 Update

*2026-05-12 18:03 UTC · Science · 1 min read*

> Memorial Sloan Kettering reports 87.5% of immune responders to BioNTech autogene cevumeran mRNA pancreatic cancer vaccine still alive 4-6 years post-surgery.

Memorial Sloan Kettering Cancer Center's updated Phase 1 results show 7 of 8 immune responders (87.5%) to BioNTech's personalized mRNA vaccine autogene cevumeran (BNT122) remain alive 4 to 6 years after pancreatic cancer surgery, principal investigator Dr. Vinod Balachandran reported. Only 2 of 8 non-responders survived, with a median survival of 3.4 years.

The 16-patient trial paired the vaccine with chemotherapy and an immunotherapy checkpoint inhibitor. Each vaccine was custom-designed in Germany from the patient's tumor genetics and delivered within nine weeks of surgery. Standard five-year survival for pancreatic cancer sits near 13%, according to the American Cancer Society.

Balachandran called the immune response "very potent" with "exceptional durability." BioNTech and Genentech, a member of the Roche Group, are now expanding the work into a larger Phase 2 study after MSK reaffirmed the data on April 19, 2026.

## Sources

- [mskcc.org](https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out)
- [npr.org](https://www.npr.org/2026/05/12/nx-s1-5783797/pancreatic-cancer-breakthroughs-daraxonrasib-mrna)

---
TechTools News · https://techtools.cz/tools/news/article/1636-biontech-autogene-cevumeran-mrna-vaccine-keeps-87-5-of-pancreatic-cancer
Česká verze: https://techtools.cz/tools/news/clanek/1709-mrna-vakcina-biontechu-autogene-cevumeran-udrzela-87-5-responderu-s-rakovinou
